Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease
- First Online:
- Cite this article as:
- Plans-Rubió, P. Pharmacoeconomics (1998) 13: 623. doi:10.2165/00019053-199813050-00014
This study assessed the cost effectiveness of treatments for the primary prevention of coronary heart disease in Spain, which included smoking cessation and reductions in blood cholesterol levels and BP. Cost-effectiveness ratios (measured in terms of $US per life-year gained) ranged from $US2608 to $US8058 per life-year gained for therapies aimed at smoking cessation, from $US7061 to $US126 990 per life-year gained for antihypertensive drug treatment, from $US15 487 to $US1689 022 per life-year gained for the drug treatment of hypercholesterolaemia and from $US12 792 to $US149 246 per life-year gained for cholesterol-lowering diets. In individuals with blood cholesterol levels of 7.7 mmol/L, cost-effectiveness ratios of drug treatment ranged from $US33 850 to $US302 088. Cost-effectiveness ratios were lower in men than in women for all programmes evaluated.
Cost-effectiveness analysis of cholesterol-lowering drugs indicated that lovastatin (HMG-CoA reductase inhibitor) was more cost effective than cholestyramine (bile acid sequestrant) and gemfibrozil (fibrate). Hydrochlorothiazide, propranolol and nifedipine were more cost effective antihypertensive treatments than prazosin and captopril. Cost-effectiveness ratios obtained in this study could be used to develop disease management strategies to facilitate the efficient use of healthcare resources and to reduce costs. When resources for coronary heart disease are limited, available treatments should be selected on the basis of their average and incremental cost-effectiveness ratios.
Unable to display preview. Download preview PDF.